Maria
Grunwald PhD, MBA

Chief Business Officer

A results-focused executive with a track record of 50+ signed agreements at early- to late-stage private and public biotech companies — Maria Grunwald is drawing on her nearly two decades of M&A, partnerships, strategy and licensing experience as she leads our partnering and licensing discussions. Her previous business development experience included, among others, positions at: Dyax (acquired by Shire for $5.9 billion), AesRx (acquired by Baxter), Dicerna [DRNA], Genevant, Radius Health, and QurAlis. She received graduate degrees from the Universities of Hannover and Cologne and performed her PhD studies in neuroscience and molecular biology at the Johns Hopkins University School of Medicine. She also holds an MBA from the MIT Sloan School of Management.